Veracyte Q2 2024 Adj. EPS $0.30 Beats $(0.02) Estimate, Sales $114.428M Beat $100.275M Estimate
Portfolio Pulse from Benzinga Newsdesk
Veracyte (NASDAQ:VCYT) reported Q2 2024 adjusted EPS of $0.30, significantly beating the analyst estimate of $(0.02). The company also reported sales of $114.428 million, surpassing the $100.275 million estimate and marking a 26.69% increase from the same period last year.
August 06, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Veracyte's Q2 2024 earnings and sales significantly exceeded analyst expectations, with EPS of $0.30 beating the $(0.02) estimate and sales of $114.428 million surpassing the $100.275 million estimate. This strong performance is likely to positively impact the stock price in the short term.
The significant beat on both EPS and sales, along with a notable year-over-year increase in sales, indicates strong financial performance. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100